Showing results (1-10 of 74) with videos related to
Sort By:
Pageof 8
Trends in Immunology|July 13, 2021
Targeting butyrophilins for cancer immunotherapyMarc Rigau, Adam P Uldrich, Andreas BehrenInternational Journal of Oncology|July 3, 2010
Influence of HPV16 E2 and its localisation on the expression of matrix metalloproteinase-9Sabrina Mühlen, Andreas Behren, Thomas Iftner, et al.Future Oncology (London, England)|July 24, 2014
Evolving role of tumor antigens for future melanoma therapiesMiles C Andrews, Katherine Woods, Jonathan Cebon, et al.Frontiers in Bioscience (Landmark Edition)|January 2, 2015
The role of circulating microRNA in hepatocellular carcinomaSimon Chang-Hao Tsao, Andreas Behren, Jonathan Cebon, et al.Virus Research|October 28, 2008
AP-1 and ERK1 but not p38 nor JNK is required for CRPV early protein 2-dependent MMP-9 promoter activation in rabbit epithelial cellsSabrina Mühlen, Andreas Behren, Thomas Iftner, et al.Immunology and Cell Biology|February 3, 2018
The good, the (not so) bad and the ugly of immune homeostasis in melanomaJessica da Gama Duarte, Katherine Woods, Miles C Andrews, et al.Frontiers in Immunology|July 26, 2022
γδ T Cells in the Tumor Microenvironment-Interactions With Other Immune CellsKok Fei Chan, Jessica Da Gama Duarte, Simone Ostrouska, et al.Expert Review of Clinical Immunology|June 19, 2014
Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatmentLaura J Vella, Miles C Andrews, Andreas Behren, et al.Nature Communications|April 18, 2018
Characterising the phenotypic evolution of circulating tumour cells during treatmentSimon Chang-Hao Tsao, Jing Wang, Yuling Wang, et al.Neoplasia (New York, N.Y.)|October 1, 2017
Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβLaura J Vella, Andreas Behren, Bradley Coleman, et al.Pageof 8